Idexx Laboratories price target raised to $590 from $582 at Barclays

Barclays analyst Balaji Prasad raised the firm’s price target on Idexx Laboratories to $590 from $582 and keeps an Overweight rating on the shares. The analyst says the above-consensus guidance sets up the company for a healthy outlook for 2023. The firm believes Idexx’s underlying fundamentals are intact.